This section is devoted to the Contract Manufacturing of Pharmaceuticals at the facilities of independent producers, who are fully compliant with technological processes and Quality Control in accordance with client requirements
Pharmaceutical Contract Manufacturing. Technology Transfer
Types of Contractors
- Manufacturers, who specialize only in Contract Manufacturing
- Manufacturers, who produce their own brands along with Contract Manufacturing
Types of Contract Services
- Full-cycle manufacturing
- Performing only some of the manufacturing operations (ex. packaging)
Canon Medical System Corporation completed the acquisition of the majority shares of ACTmed, a joint venture company established with ACT Genomics, a Taiwanese molecular diagnostic company.
Nacimbio has completed the first phase of clinical trials of the rotavirus vaccine. The new drug will be packaged in Russia in 2020 already, while the full production cycle will be launched in 2026.
According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.
Takara Bio announced that the Medical Products Agency granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions.
The global pharmaceutical company Takeda announces the opening of a production site at its plant in Yaroslavl for manufacturing Ixazomib, an innovative drug for patients with multiple myeloma.
PIK-PHARMA has successfully localized full-cycle manufacturing of Magnerot, a popular drug of WÖRWAG Pharma GmbH from Germany, at the facilities of PIK-PHARMA LEK site.
NewStem, a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness, announced a $4 million financing.
By the end of this year, Belarus and Tajikistan may elaborate a roadmap to establish joint ventures in the pharmaceutical industry, announced Oleg Ivanov, the Ambassador of Belarus in Tajikistan and Afghanistan.
Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).